Characterisation of Particle Size and Viability of SARS-CoV-2 Aerosols from a Range of Nebuliser Types Using a Novel Sampling Technique.
SARS-CoV-2
aerosols
particles
respirable
sampling
sizing
viable
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
19 03 2022
19 03 2022
Historique:
received:
15
02
2022
revised:
07
03
2022
accepted:
17
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
2
4
2022
Statut:
epublish
Résumé
Little is understood about the impact of nebulisation on the viability of SARS-CoV-2. In this study, a range of nebulisers with differing methods of aerosol generation were evaluated to determine SARS-CoV-2 viability following aerosolization. The aerosol particle size distribution was assessed using an aerosol particle sizer (APS) and SARS-CoV-2 viability was determined after collection into liquid media using All-Glass Impingers (AGI). Viable particles of SARS-CoV-2 were further characterised using the Collison 6-jet nebuliser in conjunction with novel sample techniques in an Andersen size-fractioning sampler to predict lung deposition profiles. Results demonstrate that all the tested nebulisers can generate stable, polydisperse aerosols (Geometric standard deviation (GSD) circa 1.8) in the respirable range (1.2 to 2.2 µm). Viable fractions (VF, units PFU/particle, the virus viability as a function of total particles produced) were circa 5 × 10
Identifiants
pubmed: 35337046
pii: v14030639
doi: 10.3390/v14030639
pmc: PMC8950415
pii:
doi:
Substances chimiques
Aerosols
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medical Research Council
ID : MC_PC_19064
Pays : United Kingdom
Organisme : Medical Research Council
ID : COV220-143 COVID-19
Pays : United Kingdom
Références
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Phys Fluids (1994). 2020 Oct 1;32(10):101903
pubmed: 33100806
J Ethnopharmacol. 2021 Jun 28;274:114082
pubmed: 33813012
J Bacteriol. 1958 Nov;76(5):471-84
pubmed: 13598704
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684
pubmed: 33251966
BMC Infect Dis. 2019 Jan 31;19(1):101
pubmed: 30704406
Indoor Air. 2021 Nov;31(6):1874-1885
pubmed: 34124803
Environ Int. 2020 Nov;144:106039
pubmed: 32822927
J Hyg (Lond). 1969 Sep;67(3):437-48
pubmed: 5258223
Appl Environ Microbiol. 2021 Jul 27;87(16):e0049721
pubmed: 34085856
JAMA. 2020 Jul 14;324(2):141-142
pubmed: 32478797
JAMA. 2020 Aug 4;324(5):441-442
pubmed: 32749495
J Hosp Infect. 2021 Aug;114:163-166
pubmed: 34098048
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Pulm Pharmacol Ther. 2016 Apr;37:37-42
pubmed: 26747025
Lancet Respir Med. 2020 Sep;8(9):914-924
pubmed: 32717211
J Aerosol Med Pulm Drug Deliv. 2010 Jun;23(3):173-80
pubmed: 20500093
Virulence. 2013 Nov 15;4(8):847-58
pubmed: 24225380
Nat Commun. 2021 Aug 17;12(1):4985
pubmed: 34404778
J Appl Microbiol. 2011 Aug;111(2):350-9
pubmed: 21651681
Am J Respir Crit Care Med. 2016 Aug 1;194(3):308-16
pubmed: 26890617
PLoS One. 2016 Jun 16;11(6):e0157887
pubmed: 27311020
J Pharmacol Toxicol Methods. 2004 Jan-Feb;49(1):39-55
pubmed: 14670693
Clin Infect Dis. 2020 Dec 3;71(9):2311-2313
pubmed: 32628269
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Aerobiologia (Bologna). 2007;23(4):239-248
pubmed: 32214623
Science. 2020 Oct 16;370(6514):303-304
pubmed: 33020250
Inhal Toxicol. 2003 May;15(6):619-38
pubmed: 12692733
Virol J. 2010 Sep 15;7:231
pubmed: 20843329
Environ Res. 2020 Sep;188:109819
pubmed: 32569870
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Appl Environ Microbiol. 2021 Jun 25;87(14):e0052621
pubmed: 33962986
Viruses. 2021 Nov 09;13(11):
pubmed: 34835057
Health Sci Rep. 2021 May 07;4(2):e275
pubmed: 33977157